|
| 37423297 | An academia-driven compassionate use program for patients with recurrent H3K27-altered diffuse midline glioma: a new way to access innovation when clinical trials are lacking. | | 2023 |
| 36130314 | Paediatric Inflammatory Bowel Disease: A Multi-Stakeholder Perspective to Improve Development of Drugs for Children and Adolescents. | | 2023 |
| 36400105 | Cancer research in Europe: a focus on children and young people. | Lancet Oncology, The | 2023 |
| 37549532 | Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial. | Eur J Cancer | 2023 |
| 37857712 | AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial. | Nat Med | 2023 |
| 36510699 | Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children. | | 2023 |
| 37399010 | Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study. | | 2023 |
| 36961477 | Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator. | Oncologist | 2023 |
| 36645217 | Changing incentives to ACCELERATE drug development for paediatric cancer. | Cancer Med | 2023 |
| 37015036 | Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents. | J Clin Oncol | 2023 |
| 37384865 | Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis. | | 2023 |
| 36939456 | Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions. | | 2023 |
| 37441939 | Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2023 |
| 37377921 | Longitudinal characterization of primary osteosarcoma and derived subcutaneous and orthotopic relapsed patient-derived xenograft models. | Front Oncol | 2023 |
| 37432135 | Predictive factors of long-term follow-up attendance in very long-term childhood cancer survivors. | Cancer | 2023 |
| 36682367 | Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents. | | 2023 |
| 36528416 | Paediatric drug development and evaluation: Existing challenges and recommendations. | | 2023 |
| 35078815 | Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis. | Cancer Res | 2022 |
| 35901818 | The impact of the EU General Data Protection Regulation on childhood cancer research in Europe. | Lancet Oncol | 2022 |
| 35631381 | Development of a Hospital Compounded, Taste-Masked, Temozolomide Oral Suspension and 5-Year Real-Life Experience in Treating Paediatric Patients. | Pharmaceuticals | 2022 |
| 36335782 | Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 36332647 | Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE. | Lancet Oncology, The | 2022 |
| 36328007 | ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development? | Lancet Oncol | 2022 |
| 35863108 | Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 35672677 | Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib. | BMC Cancer | 2022 |
| 35412366 | MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial. | Radiology | 2022 |
| 35671543 | Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours. | Eur J Cancer | 2022 |
| 36252166 | How Can Genomic Innovations in Pediatric Brain Tumors Transform Outcomes in Low- and Middle-Income Countries? | JCO Glob Oncol | 2022 |
| 35780527 | QUARTET: A SIOP Europe project for quality and excellence in radiotherapy and imaging for children and adolescents with cancer. | Eur J Cancer | 2022 |
| 35292802 | The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies. | Cancer Discov | 2022 |
| 35290915 | ACCELERATE - Five years accelerating cancer drug development for children and adolescents. | Eur J Cancer | 2022 |
| 35235871 | Market access to new anticancer medicines for children and adolescents with cancer in Europe. | European Journal of Cancer | 2022 |
| 34963094 | Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies. | Eur J Cancer | 2022 |
| 34840026 | Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 34994601 | <i>NTRK</i> Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets. | JCO Precis Oncol | 2021 |
| 33860611 | A global approach to long-term follow-up of targeted and immune-based therapy in childhood and adolescence. | Pediatr Blood Cancer | 2021 |
| 34169282 | Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients. | Neurooncol Adv | 2021 |
| 33847874 | The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program. | Targeted Oncology | 2021 |
| 34278817 | Precision oncology: a clinical and patient perspective. | Future Oncol | 2021 |
| 33892407 | Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cance | European Journal of Cancer | 2021 |
| 34157616 | Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies. | European Journal of Cancer | 2021 |
| 34108262 | International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer. | Mol Cancer Ther | 2021 |
| 33452711 | Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research. | Cancer Medicine | 2021 |
| 33601323 | Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. | Eur J Cancer | 2021 |
| 34347542 | Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial. | Journal of Clinical Oncology | 2021 |
| 33340549 | Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation. | Journal of Pediatrics | 2021 |
| 32896951 | Precision medicine at its best: Prolonged survival in a child presenting a secondary mesothelioma treated with crizotinib. | Pediatric Blood and Cancer | 2021 |
| 33388384 | Access to essential anticancer medicines for children and adolescents in Europe. | Annals of Oncology | 2021 |
| 34687165 | Intercontinental collaboration in clinical trials for children and adolescents with cancer-A systematic review by ACCELERATE. | Cancer Med | 2021 |
| 34570655 | Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. | J Clin Oncol | 2021 |